B6-hDMD (E44-45) Mice

Catalog Number: I001204

Strain Name: C57BL/6NCya-Dmdtm2(hDMD Exon 44-45)/Cya

Genetic Background: C57BL/6NCya

One of Cyagen's HUGO-GT™ (Humanized Genomic Ortholog for Gene Therapy) Strains

 

Strain Description

Duchenne Muscular Dystrophy (DMD) is a severe, progressive, and disabling X-linked recessive genetic disorder characterized primarily by muscle atrophy. This disease leads to motor impairments, eventually requiring assisted ventilation, and often results in premature death. The primary cause of DMD is mutations in the DMD gene, which encodes the dystrophin protein. These mutations lead to a reduction or absence of dystrophin in muscle tissue, resulting in muscle atrophy and related complications [1]. The lack of dystrophin leads to the breakdown of the dystrophin-associated protein complex (DAPC) within the muscle membrane, disrupting the interaction between actin and the extracellular matrix, making the muscles more susceptible to damage. This susceptibility results in the gradual loss of muscle tissue and function, potentially leading to cardiomyopathy [2]. Researchers have identified thousands of different DMD gene mutations in patients with DMD. Deletion mutations account for approximately 60%–70%, while duplication mutations account for 5%–15%. These mutations are primarily concentrated in hotspot regions of the DMD gene, specifically between exons 45-55 (47%) and exons 3-9 (7%) [1].

Currently, gene therapy approaches for Duchenne Muscular Dystrophy (DMD) primarily include exon skipping and AAV supplementation, as well as emerging gene editing techniques like CRISPR. The exon skipping strategy involves using antisense oligonucleotide (ASO) drugs to bind to specific sequences of pre-mRNA, skipping the mutated exon and restoring the open reading frame (ORF) integrity, thus producing a truncated but partially functional dystrophin protein. Several ASO drugs targeting the DMD gene have been approved, such as Eteplirsen (targeting exon 51), Golodirsen (targeting exon 53), and Casimersen (targeting exon 45) developed by Sarepta, and Viltolarsen (targeting exon 53) developed by Nippon Shinyaku. Since most ASO and CRISPR-based gene editing therapies target the human DMD gene, humanizing mouse genes helps accelerate clinical applications for DMD therapies, considering the genetic differences between animals and humans.

The B6-hDMD (E44-45) mouse is a humanized model of exons 44-45 of the mouse Dmd gene, used for researching Duchenne Muscular Dystrophy. Homozygotes are viable and fertile. In addition, based on the independently developed TurboKnockout fusion BAC recombination technology, Cyagen provides other humanized models such as [hE49-53, del E50], [hE49-53], [hE44-45, del E44], [hE44-45, c.6438+2 T to A], [hE8-30], covering most popular research areas and offering customized services based on different mutation needs.

Strain Strategy


Figure 1. Gene editing strategy of B6-hDMD (E44-45) mice. The sequences from ~2.5 kb upstream of exon 44 to ~2.9 kb downstream of exon 45 of mouse Dmd were replaced with human DMD exon 44 plus flanking region (~2.5 kb upstream of exon 44 to ~2.5 kb downstream of exon 44)-human DMD exon 45 plus flanking region (~2.5 kb upstream of exon 45 to ~3 kb downstream of exon 45) cassette.

Application

  • Research on the pathogenesis of Duchenne Muscular Dystrophy (DMD);
  • Preclinical efficacy evaluation of DMD therapeutic drugs.

 

Validation Data

1. RT-PCR

Figure 2. RT-PCR detection of gene expression in B6-hDMD (E44-45) mice. cDNA was obtained by reverse transcription using primers specifically paired with human DMD mRNA, followed by gel electrophoresis to determine the expression of the human DMD gene. The result shows the presence of human DMD cDNA bands in both the brain and muscle tissues of B6-hDMD (E44-45) mice, with band sizes matching expected values and no abnormal transcription bands observed.

2. cDNA sequencing

Figure 3. Gene sequencing results of the exon 44-45 region in B6-hDMD (E44-45) mice. Sequencing analysis of the DMD cDNA, reverse-transcribed from mRNA detected in the RT-PCR test, shows that the exon 44-45 region of the Dmd gene in B6-hDMD (E44-45) mice corresponds to the respective sequences in the human DMD gene, with nucleotide sequences identical to the reference sequences in the human DMD gene.

3. Gene expression

Figure 4. RT-qPCR analysis in 6-week-old male homozygous B6-hDMD(E44-45) and wild-type (WT) mice. The results indicate that the human DMD gene is significantly expressed in the skeletal muscle, cerebral cortex, and heart of B6-hDMD(E44-45) mice, while no expression is detected in wild-type mice. The mouse Dmd gene is significantly expressed in wild-type mice but not in B6-hDMD(E44-45) mice. (Bars represent mean ± SEM, n=3)

Note: The primers that detect the expression of the human DMD gene and the mouse Dmd gene target the Exon 45.

4. Protein expression

Figure 5. Western blot analysis of DMD protein expression in 6-week-old male homozygous B6-hDMD(E44-45) and wild-type (WT) mice. The Western Blot analysis shows that B6-hDMD(E44-45) mice normally express the DMD protein in skeletal muscle, cerebral cortex, and heart.

Note: The antibody used for detecting mouse DMD protein targets aa. 3550-3678. The gene sequence encoding this binding region is located after the humanized sequence (approximately in the exon 78-79 region).

5. Serum Creatine Kinase (CK) Level

Figure 6. Serum creatine kinase (CK) levels in 6-week-old male homozygous B6-hDMD(E44-45) and wild-type (WT) mice. Creatine kinase is a component of the myocardial enzyme spectrum, and elevated serum creatine kinase levels are related to muscle and myocardial damage. The blood biochemical results show that the CK values in B6-hDMD(E44-45) mice are similar to those in wild-type mice. (Bars represent mean ± SEM, n≥3)

 

 

References

[1] Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021 Feb 18;7(1):13.

[2] Babbs A, Chatzopoulou M, Edwards B, Squire SE, Wilkinson IVL, Wynne GM, Russell AJ, Davies KE. From diagnosis to therapy in Duchenne muscular dystrophy. Biochem Soc Trans. 2020 Jun 30;48(3):813-821.